“We are thrilled and honored that Wisconsin Fertility Institute has been recognized as one of America’s Best Fertility Clinics by Newsweek in 2025,” commented Steve Shum, CEO of INVO Fertility.

SARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access ...

INVO Fertility, Inc. (NASDAQ:IVF), a medical device company with a market capitalization of $1.61 million, has entered into a material definitive agreement with an institutional investor, as ...

INVO Fertility Inc (NASDAQ:IVF) shares are soaring on Wednesday after the company reported financial results for the fourth quarter.

SARASOTA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to ...

Having picked up a pipeline of oncology drugs as part of a merger last year, NAYA Biosciences is reverting back to its original focus of fertility and spinning off the cancer business. Before the ...

NAYA Biosciences has changed its name to INVO Fertility and will separate its fertility and oncology operations. The Sarasota, Fla., company said Monday the decision to separate its two main focus ...

Nitto Tires are the supporter-of-choice for plenty of motorsports events, and many of its tires receive high ratings for day-to-day and enthusiast driving.

Converting firm Nitto is shuttering three plants—resulting in the loss of 298 jobs total—in Alabama, Ohio and Virginia, and will add 220 jobs with the opening of a new facility in Kentucky.

Combined company to expand portfolio of clinical & commercial-stage assets in fertility, oncology, and autoimmune diseases SARASOTA, Fla. and MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience ( ...

SARASOTA, FL – INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company specializing in fertility treatment, has entered into a financial agreement that provides an immediate cash injection to ...

INVO Bioscience (NASDAQ: INVO) just reported results for the second quarter of 2024. INVO Bioscience reported earnings per share of -62 cents. The company reported revenue of $1.84 million.